



3 November 2008

## **FDA accepts Arana's anti-inflammatory IND**

Biotechnology company Arana Therapeutics Limited (ASX: AAH) today announced that lead anti-inflammatory compound, ART62I has successfully passed review of its rheumatoid arthritis Investigational New Drug (IND) application by the US Food and Drug Administration (FDA).

IND status indicates regulatory approval to conduct clinical trials in humans in the United States and represents the first review of ART62I data by a major Regulatory Authority.

Arana can now proceed with its planned Phase II study in rheumatoid arthritis.

Dr John Chiplin Arana's CEO said "We are delighted with this positive result which validates Arana's technology and development expertise. Crucially, an open IND increases our commercial visibility and is an important catalyst for our ongoing partnering discussions."

"Arana is at the forefront of new antibody technologies and we are one of the few companies to have second generation antibody products in clinical trials."

"We look forward to commencing our Phase II rheumatoid arthritis programme by the end of this year," he added.

Arana Therapeutics Limited  
Level 2 37 Epping Road  
Macquarie Park  
Sydney, NSW 2113  
Australia  
P + 61 2 8061 9900  
F + 61 2 8061 9999  
ABN 98 002 951 877

**About Arana Therapeutics:**

Arana Therapeutics (ASX: AAH) is an international biopharmaceutical company focussed on developing next generation antibody based drugs that will improve the lives of patients with inflammatory diseases and cancer.

Arana Therapeutics' innovative engineering technologies provide the basis for developing its next generation antibody candidates. Arana Therapeutics has the financial strength and management expertise to develop its product pipeline.

Arana has a significant track record of commercialising its technologies and has partnerships with GSK, CSL, Centocor (J&J) and Abbott Laboratories.

For further information: [www.arana.com](http://www.arana.com)

**Contact information:****Company:**

John Chiplin  
Chief Executive Officer  
Arana Therapeutics  
T: + 61 2 8061 9900  
E: [jchiplin@arana.com](mailto:jchiplin@arana.com)

**Investor & Media Relations:**

Paul Dekkers  
Buchan Consulting  
T: + 61 2 9237 2800  
Mobile: 0418 218 722  
E: [pdekkers@bcg.com.au](mailto:pdekkers@bcg.com.au)